Reference is made to the Annual General Meeting inAker BioMarine held on20 April 2022 in which Mr. Øyvind Eriksen was appointed as deputy member to the Board of Directors. The Board of Directors has on8 June 2022 appointedMr. Eriksen as an observer to the Board.Mr. Eriksen will consequently resign as deputy member. For further information, please contactCarl Christian Bachke , Investor Relations Mobile: +47 909 808 48 Email: carl.bachke@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source